AU2018323470B2 - Anti-TM4SF1 antibodies and methods of using same - Google Patents

Anti-TM4SF1 antibodies and methods of using same Download PDF

Info

Publication number
AU2018323470B2
AU2018323470B2 AU2018323470A AU2018323470A AU2018323470B2 AU 2018323470 B2 AU2018323470 B2 AU 2018323470B2 AU 2018323470 A AU2018323470 A AU 2018323470A AU 2018323470 A AU2018323470 A AU 2018323470A AU 2018323470 B2 AU2018323470 B2 AU 2018323470B2
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
domain
tm4sf1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018323470A
Other languages
English (en)
Other versions
AU2018323470A1 (en
Inventor
Harold F. Dvorak
Paul A. JAMINET
Shou-Ching S. Jaminet
Leonard G. Presta
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Angiex Inc
Original Assignee
Angiex Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Angiex Inc filed Critical Angiex Inc
Publication of AU2018323470A1 publication Critical patent/AU2018323470A1/en
Application granted granted Critical
Publication of AU2018323470B2 publication Critical patent/AU2018323470B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/77—Internalization into the cell
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2018323470A 2017-08-28 2018-08-28 Anti-TM4SF1 antibodies and methods of using same Active AU2018323470B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762550994P 2017-08-28 2017-08-28
US62/550,994 2017-08-28
PCT/US2018/048402 WO2019046338A1 (en) 2017-08-28 2018-08-28 ANTI-TM4SF1 ANTIBODIES AND METHODS OF USE

Publications (2)

Publication Number Publication Date
AU2018323470A1 AU2018323470A1 (en) 2020-03-19
AU2018323470B2 true AU2018323470B2 (en) 2025-04-24

Family

ID=65526015

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018323470A Active AU2018323470B2 (en) 2017-08-28 2018-08-28 Anti-TM4SF1 antibodies and methods of using same

Country Status (8)

Country Link
US (3) US11208495B2 (enExample)
EP (1) EP3675906A4 (enExample)
JP (2) JP7241080B2 (enExample)
CN (1) CN111565750B (enExample)
AU (1) AU2018323470B2 (enExample)
CA (1) CA3074111A1 (enExample)
MX (1) MX2020002241A (enExample)
WO (1) WO2019046338A1 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017091698A1 (en) 2015-11-24 2017-06-01 Massachusetts Institute Of Technology Systems and methods for preventing, mitigating, and/or treating dementia
KR102612531B1 (ko) 2016-11-17 2023-12-12 코그니토 쎄라퓨틱스, 인코포레이티드 인지 기능 개선을 위한 시스템
JP7241080B2 (ja) * 2017-08-28 2023-03-16 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法
WO2019074637A1 (en) 2017-10-10 2019-04-18 Massachusetts Institute Of Technology SYSTEMS AND METHODS FOR PREVENTION, MITIGATION AND / OR TREATMENT OF DEMENTIA
WO2019241430A2 (en) * 2018-06-12 2019-12-19 Angiex, Inc. Antibody-oligonucleotide conjugates
US12428477B2 (en) 2019-02-27 2025-09-30 Angiex, Inc. Antibody-drug conjugates comprising anti-TM4SF1 antibodies and methods of using the same
CN110734494B (zh) * 2019-10-30 2021-04-30 上海市第一人民医院 抗tspan8单克隆抗体及其用途
EP4126042A2 (en) * 2020-03-27 2023-02-08 Angiex, Inc. Degrader-antibody conjugates and methods of using same
WO2021222783A1 (en) * 2020-05-01 2021-11-04 Angiex, Inc. Anti-tm4sf1 antibody drug conjugates and methods of using same
EP4188449A4 (en) * 2020-07-31 2025-12-17 Angiex Inc ANTI-TM4SF1 ANTIBODY AGENT CONJUGATES WITH CRISPABLE LINKERS AND METHOD FOR USE THEREMISH
AU2022242927A1 (en) * 2021-03-26 2023-10-05 Angiex, Inc. Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
EP4313009A4 (en) * 2021-03-26 2025-12-10 Angiex Inc Maytansin-antibodies conjugate and their methods of use
KR102840561B1 (ko) * 2021-06-03 2025-08-01 주식회사 메드팩토 Tm4sf19 억제제 및 이의 용도
WO2022255401A1 (ja) * 2021-06-03 2022-12-08 国立大学法人 東京大学 Ｅｒｋ－ｍａｐｋ経路の異常な活性化に伴い発現する疾患マーカー

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
EP0940468A1 (en) 1991-06-14 1999-09-08 Genentech, Inc. Humanized antibody variable domain
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
FI941572A7 (fi) 1991-10-07 1994-05-27 Oncologix Inc Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenete lmä
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
BR9813365A (pt) 1997-12-05 2004-06-15 Scripps Research Inst Método para produção e humanização de um anticorpo monoclonal de rato
PT1068241E (pt) 1998-04-02 2007-11-19 Genentech Inc Variantes de anticorpos e respectivos fragmentos
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
AU2003225669A1 (en) 2002-09-26 2004-04-19 Pintex Pharmaceuticals, Inc. Pin1-modulating compounds and methods of use thereof
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
MXPA06011199A (es) 2004-03-31 2007-04-16 Genentech Inc Anticuerpos anti-tgf-beta humanizados.
EP2175884B8 (en) 2007-07-12 2017-02-22 GITR, Inc. Combination therapies employing gitr binding molecules
CN101952454B (zh) 2008-02-08 2014-06-04 米迪缪尼有限公司 具有减弱的Fc配体亲和性的抗IFNAR1抗体
WO2010073694A1 (ja) * 2008-12-25 2010-07-01 国立大学法人東京大学 抗tm4sf20抗体を用いた癌の診断と治療
HUE041335T2 (hu) 2011-03-29 2019-05-28 Roche Glycart Ag Antitest FC-variánsok
KR20140059168A (ko) 2011-04-21 2014-05-15 더 리젠츠 오브 더 유니버시티 오브 콜로라도, 어 바디 코포레이트 시신경 척수염 치료용 조성물 및 치료 방법
CN102590531A (zh) * 2012-03-24 2012-07-18 广西壮族自治区肿瘤防治研究所 卵巢癌相关抗原自身抗体谱液相芯片检测试剂盒及其制备方法
JP6534654B2 (ja) * 2013-10-10 2019-06-26 ベス イスラエル デアコネス メディカル センター インコーポレイティッド Ｔｍ４ｓｆ１結合性タンパク質およびそれを使用する方法
HRP20210957T1 (hr) 2013-11-22 2021-09-17 Sabre Therapeutics Llc Spojevi inhibitori autotaksina
TW202132337A (zh) * 2014-05-28 2021-09-01 美商艾吉納斯公司 抗糖皮質素誘導性ｔｎｆｒ家族相關性受體（ｇｉｔｒ）抗體類及使用彼等之方法
JP7241080B2 (ja) * 2017-08-28 2023-03-16 アンジーエックス・インコーポレーテッド 抗ｔｍ４ｓｆ１抗体およびそれを使用する方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
A. VISINTIN ET AL, MOLECULAR CANCER THERAPEUTICS, vol. 14, no. 8, 18 June 2015 (2015-06-18), US, pages 1868 - 1876, XP055578657, ISSN: 1535-7163, DOI: 10.1158/1535-7163.MCT-15-0188 *
FELL H P ET AL: "Chimeric L6 antitumor antibody", JOURNAL OF BIOLOGICAL CHEMISTRY, AMERICAN SOCIETY FOR BIOCHEMISTRY AND MOLECULAR BIOLOGY, vol. 267, no. 22, 5 August 1992 (1992-08-05), pages 15552 - 15558, XP002963048, ISSN: 0021-9258 *

Also Published As

Publication number Publication date
WO2019046338A1 (en) 2019-03-07
EP3675906A4 (en) 2021-05-26
CN111565750B (zh) 2023-11-03
JP7241080B2 (ja) 2023-03-16
AU2018323470A1 (en) 2020-03-19
US20220153860A1 (en) 2022-05-19
MX2020002241A (es) 2020-09-03
US20220267461A1 (en) 2022-08-25
EP3675906A1 (en) 2020-07-08
CA3074111A1 (en) 2019-03-07
JP2023071888A (ja) 2023-05-23
US11208495B2 (en) 2021-12-28
US20200270360A1 (en) 2020-08-27
CN111565750A (zh) 2020-08-21
JP2020534351A (ja) 2020-11-26

Similar Documents

Publication Publication Date Title
AU2018323470B2 (en) Anti-TM4SF1 antibodies and methods of using same
US9469688B2 (en) Therapeutic DLL4 binding proteins
AU2022203601A1 (en) Therapeutic antibodies and their uses
AU2021366691B2 (en) Anti-FGFR2 antibodies and methods of use thereof
US20210009681A1 (en) Therapeutic DLL4 Binding Proteins
AU2019202725A1 (en) Prolactin receptor binding proteins and uses thereof
WO2022026915A2 (en) Anti-tm4sf1 antibody-drug conjugates comprising cleavable linkers and methods of using same
US20230372518A1 (en) Antimitotic tetrapeptide-antibody conjugates and methods of using same
JP2025061007A (ja) 抗ｔｍ４ｓｆ１抗体を含む抗体薬物コンジュゲートおよびそれを使用する方法
US20240166759A1 (en) Combinations comprising anti-tm4sf1 antibodies and immunotherapeutic agents and methods of using the same
US20230212300A1 (en) Human endothelin receptor a (etar) antagonist antibodies
HK1199209A1 (en) Vegf/dll4 binding agents and uses thereof
HK1199209B (en) Vegf/dll4 binding agents and uses thereof
AU2015202980A1 (en) Therapeutic DLL4 binding proteins
HK1229347A (en) Therapeutic dll4 binding proteins
HK1229347A1 (en) Therapeutic dll4 binding proteins

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)